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Background: In recent years, Nocardia farcinica has been reported to be an increasingly frequent cause of localized
and disseminated infections in the immunocompromised patient. However, recent literature is limited. We report a
case of left thigh phlegmon caused by N. farcinica that occurred in a patient with Leprosy undergoing treatment
with prednisone for leprosy reaction.
Case presentation: We describe the case of left thigh phlegmon caused by Nocardia farcinica in a 54-year-old
Italian man affected by multi-bacillary leprosy. The patient had worked in South America for 11 years. Seven
months after his return to Italy, he was diagnosed with Leprosy and started multi-drug antibiotic therapy plus
thalidomide and steroids. Then, during therapy with rifampicin monthly, minocycline 100 mg daily, moxifloxacin
400 mg daily, and prednisone (the latter to treat type 2 leprosy reaction), the patient complained of high fever
associated with erythema, swelling, and pain in the left thigh. Therefore, he was admitted to our hospital with the
clinical suspicion of cellulitis. Ultrasound examination and Magnetic Resonance Imaging showed left thigh
phlegmon. He was treated with drainage and antibiotic therapy (meropenem and vancomycin replaced by
daptomycin). The responsible organism, Nocardia farcinica, was identified by 16S rRNA sequencing in the purulent
fluid taken out by aspiration. The patient continued treatment with intravenous trimethoprim/sulfamethoxazole and
imipenem followed by oral trimethoprim/sulfamethoxazole and moxifloxacin. A whole-body computed
tomography did not reveal dissemination to other organs like the lung or brain.
The patient was discharged after complete remission. Oral therapy with trimethoprim/sulfamethoxazole,
moxifloxacin, rifampicin monthly, clofazimine and thalidomide was prescribed to be taken at home. One
month after discharge from the hospital the patient is in good clinical condition with complete resolution of
the phlegmon.
Conclusion: N. farcinica is a rare infectious agent that mainly affects immunocompromised patients. Presentation of
phlegmon only without disseminated infection is unusual, even in these kinds of patients. In any case, a higher
index of suspicion is needed, as diagnosis can easily be missed due to the absence of characteristic symptoms and
the several difficulties usually encountered in identifying the pathogen.
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Nocardiosis is a localized or disseminated uncommon in-
fection caused by an aerobic Actinomycetes of the genus
Nocardia [1]. Approximately 50 species of Nocardia have
been characterized [2], with at least 16 species being rec-
ognized as human pathogens [3]. These organisms are
opportunistic pathogens affecting immunocompromised
hosts, including those with long-term corticosteroid ex-
posure, malignancy, human immunodeficiency virus infec-
tion, and a history of transplantation [4]. Earlier reports
estimated the occurrence of 500–1,000 new cases each
year in the USA, and 150–200 and 90–130 in France
and Italy, respectively [5-7]. N. asteroides, N. farcinica and
N. nova caused approximately 85% of the total cases
[8-10]. An increase in the diagnosis of N. farcinica infec-
tion is due to the growing population of immuno-
compromised hosts and improved methods for detecting
and identifying the Nocardia species. This microorganism
can cause localized or disseminated infections that can be
life-threatening without prompt diagnosis and proper
treatment; furthermore, it is characteristically resistant to
multiple anti-microbial agents, including third-generation
cephalosporin [1,11].
We report the case of left thigh phlegmon caused by
N. farcinica that occurred in a patient affected by Lep-
rosy undergoing treatment with prednisone for leprosy
reaction.
Case presentation
A 54 year old Italian man was admitted to the “Lazzaro
Spallanzani” National Institute for Infectious Diseases of
Rome because of fever, cutaneous lesions and sensory
loss of peripheral nerves. He had worked in Venezuela
for eleven years. A histological examination of a skin
biopsy showed the presence of Mycobacterium leprae
and the patient was diagnosed as borderline leproma-
tous (BL) leprosy complicated by erythema nodosum
leprosum (ENL) reaction. His bacteriological index (total
bacterial load) was 4.17+ (normal range 0-6+) and the
morphological index (percentage of bacilli uniformly
stained) 0.5%. He was treated with rifampicin monthly
and minocycline and moxifloxacin daily. The ENL was
recurrent and treated with oral prednisone (75 mg) and
thalidomide. Sixteen months after starting therapy for
Leprosy (and after about a year of steroid therapy), the
patient started to complain of high fever (39°C) associ-
ated with erythema, swelling and pain of left thigh, and
he was admitted to our hospital for the second time with
suspicion of cellulitis. He referred that the symptoms
had started about 7 days before admission, but he denied
a history of local trauma or recreational drug abuse. Dia-
betes mellitus had been diagnosed two months before.
On physical examination, his vital signs were as fol-
lows: temperature 39°C, blood pressure 130/80 mmHg,pulse rate 95 beats per minute, and respiratory rate 15
breaths per minute. Laboratory examinations revealed:
white blood cells (WBC) 14,500/μL (4,3-10,8) (87% neu-
trophils, 4.1% lymphocytes), haemoglobin 11 g/dL (12–18),
platelets 234,000/μL (80,000 – 400,000), C-reactive protein
(CRP) 32 mg/dL (0–0.16), and erythrocyte sedimentation
rate (ESR) 82 mm/h (0–15). Chest X-ray was normal. Ultra-
sound examination and Magnetic Resonance Imaging
(MRI) of the lower extremities revealed left thigh phlegmon
(Figure 1). Ultrasound guided incision and drainage were
performed at the bedside with leaking, copious amounts
of pus. Samples were sent to the laboratory for Gram and
acid -fast bacilli staining, cultures, and PCR amplification of
bacterial DNA. Furthermore, more sets of blood cultures
were performed.
Intravenous vancomycin and meropenem were started:
500 mg every six hours, and 1 g every 8 hours, respec-
tively, and moxifloxacin and minocycline were stopped.
Incision was repeated on hospital day 3 and vancomycin
was replaced by daptomycin for the persistence of high
fever; prednisone was reduced to 50 mg. After 96 hours
of incubation, blood cultures and aerobic and anaer-
obic cultures of the sample were negative. On day 6,
the patient had type 2 leprosy reaction and prednisone
was again increased to 75 mg. Seven days after initi-
ating daptomycin, an ultrasound examination showed
the first decrease of both phlegmon volume and periph-
eral oedema.
On hospital day 15, the pathogen was identified as
N. farcinica by 16S rRNA gene sequencing in the purulent
fluid, whereas the cultures were negative. Amplified PCR
products (Figure 2) were purified and directly sequenced.
Related DNA sequences were searched in GenBank by
using the BLAST (Basic Local Alignment Search Tool)
server. The most closely related sequences belonged to
Nocardia farcinica species. The further identity of the
pathogen was also confirmed by sequencing a region of
16S rRNA gene of Nocardia with a PCR that used genus-
specific primers [12]. Sequence data of the amplified PCR
products showed great identity (99%) to the species
Nocardia farcinica
The patient was shifted to a therapy based on intra-
venous trimethoprim/sulfamethoxazole and imipenem
for 1 month. A whole-body computed tomography (CT-
scan) revealed no dissemination to other organs like the
lung or brain. On hospital day 22, prednisone was stopped
and the leprosy reaction was treated with clofazimine and
thalidomide. After a month of therapy, MRI revealed a de-
creased amount of phlegmon without osteomyelitis of the
left femur (Figure 3).
The patient was discharged after complete remission
at day 51 with a prescription of oral trimethoprim/
sulfamethoxazole, moxifloxacin, rifampicin monthly,
clofazimine and thalidomide.
Figure 1 Magnetic Resonance Imaging of left thigh at admission. a. T1 after contrast coronal image showing hyperintense necrotic lesion of
the left thight; b. T2 FLAIR weighted sagittal image of the same lesion that appear hypointense.
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is in good clinical condition.
Conclusion
N.farcinica is a Gram–positive, branching, filamentous ba-
cillus causing many localized and disseminated infectious in
humans, including pulmonary and wound infections, brain
abscesses, and bacteraemia. Immunocompromised hosts
and patients undergoing immunosuppressive therapies are
more commonly affected by this bacterium [2].Anton Y. Peleg et al. described the risk factors of
N. farcinica infection in organ transplant recipients. In
this case series, patients with Nocardia infection had sig-
nificantly higher prednisone dosages (p 0.007), lower
lymphocyte counts (p 0.003), and higher neutrophil counts
(p 0.006) at the time of infection, compared with control
subjects [13]. In our case, the patient had undergone ther-
apy with prednisone in the preceding 12 months because
of leprosy reaction. At admission he had WBC 14,500/μL
with neutrophils 87% (11800/mmc), lymphocytes 4.1%




Figure 2 Two percent agarose gel electrophoresis showing the
product of amplification of the 798-bp fragment of the 16S
rRNA gene. DNA sequencing of such a fragment further allowed the
identification of Nocardia farcinica. Lane 1 = PCR product obtained
from a phlegmon sample of our patient; lane 2 = negative control
(water); lane 3 = positive control (Streptococcus pneumoniae ATCC
49619); M =DNA size reference marker (50-2000-bp Amplisize, Biorad).
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The relative frequency of infections caused by the dif-
ferent Nocardia species are difficult to determine retro-
spectively and may vary geographically. N. farcinica has
been reported to constitute 13,8% and 19% of NocardiaFigure 3 Magnetic Resonance Imaging performed after a month
of antibiotic therapy shows complete resolution of the phlegmon.isolates in Italy from 1982 to 1992 [14] and from 1993
to 1997 [7], respectively. It is not possible to estimate
the actual number of Italian cases due to the potential
bias of referrals to public health authorities and also be-
cause Nocardia strains are not collected at the National
Reference Centre.
The clinical manifestations of N. farcinica are different.
The lung is the most common site of infection (43%).
Torres et al. observed infections of cutaneous and sub-
cutaneous tissues in 10% of cases. In the case of dissemi-
nated infections, it was possible to detect a metastatic focus
or, more frequently, a primary lesion after traumatic injury.
In other cases, the patients had sub-clinical or transient
primary pulmonary infection followed by dissemination to
the brain, skin, bones, and kidney [15]. In our case, as in
the 7/26 cases described in an Italian report about human
Nocardiosis between 1993 and 1997 [7], it was not possible
to observe previous pulmonary involvement.
Concerning the epidemiology, Nocardiae are ubiqui-
tous in the environment and can be found worldwide
in fresh and salt water, in a variety of soil types, dust,
decaying vegetation, and decaying faecal deposits from
animals [2]. Bittar et al. described a Nocardia infection
in a man who was an active gardener [16]. Our patient
had gardening as a hobby, which led us to speculate that
he could have acquired the infection in this way.
Unfortunately, we did not identify the organism with
the cultures and could not perform susceptibility testing.
However, previous studies have identified multi-drug-
resistance patterns in isolates of N. farcinica, characterized
by resistance to most beta-lactam antibiotics [17] and sus-
ceptibility mainly to amikacin, imipenem, trimethoprim/
sulfamethoxazole, and fluoroquinolones [2]. Hansen G.
et al. reported that fluoroquinolones had variable activity
against clinical strains of Nocardia, and the newer flu-
oroquinolones such as moxifloxacin, gatifloxacin, and
gemifloxacin, had increased in vitro activity compared to
ciprofloxacin [17].
Laboratory identification and speciation for Nocardia
are challenging, and the methodology continues to evolve.
Before 2000, Nocardia isolates were identified primarily
through phenotypic methods. In 2000, the identification of
Nocardia was enhanced through the use of 16SrRna gene
sequencing in research centres [18-20]. In the reported
case, it is interesting to underline that our patient pres-
ented clinical and radiological improvement after the ini-
tiation of therapy with daptomycin. Since no cases of
N. farcinica treated with daptomycin have been described
in literature (there are only sensitivity studies in vitro) [21],
we started empirical antibiotic combination therapy with
imipenem plus trimethoprim-sulfamethoxazole. Informa-
tion on the duration of treatment is inadequately docu-
mented in most reports, varying from 3 to 12 months with
a median of 4 months. Primary cutaneous Nocardiosis
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after bone involvement has been excluded [4,6].
In summary, Nocardiosis remains a severe and some-
times potentially life-threatening complication in the im-
munocompromised host. It is relevant to consider this
microorganism in the differential diagnosis of infections,
even in cases with unusual presentations such as this one.
Because of the aggressiveness, tendency to disseminate,
and resistance of the organism to antibiotics, delayed diag-
nosis can have serious consequences.
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